Frequency of uridine monophosphate synthase Gly 213Ala polymorphism in caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays

Genetic Testing and Molecular Biomarkers

Volumn 15, Issue 10, 2011, Pages 691-695

  Gusella, Milena ^a,b   Bertolaso, Laura ^b   Bolzonella, Caterina ^b   Pasini, Felice ^a   Padrini, Roberto ^c  

^a ROVIGO GENERAL HOSPITAL   (Italy)

^b Trecenta General Hospital   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; URIDINE MONOPHOSPHATE SYNTHASE; URIDINE PHOSPHATE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CAUCASIAN; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; AMINO ACID SUBSTITUTION; CARCINOMA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROINTESTINAL NEOPLASMS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; GLYCINE; HEALTH; HUMANS; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; OROTATE PHOSPHORIBOSYLTRANSFERASE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS;

EID: 80054704520     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0021     Document Type: Article

References (17)

1. Curtin K, Bigler J, Slattery ML, et al. (2004) MTHFR C677T and A1298C polymorphisms: diet, estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 13:285-292. (Pubitemid 38222562)
2. Fujii R, Seshimo A, Kameoka S (2003) Relationship between the expression of thymidylate synthase, dihydropyrimidine de-hydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal cancer carcinoma. Int J Clin Oncol 8:72-78. (Pubitemid 36548474)
3. Goekkurt E, Al-Batran SE, Hartmann JT, et al. (2009) Pharma-cogenetic analyses of a phase III trial in metastatic gastro-esophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsge-meinschaft internistische onkologie. J Clin Oncol 27:2863-2873.
4. Ichikawa W, Takahashi T, Suto K, et al. (2006) Orotate hos-phoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 12:3928-3934. (Pubitemid 44078077)
5. Ichikawa W, Uetake H, Shirota Y, et al. (2003) Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89:1486-1492. (Pubitemid 37386604)
6. Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349. (Pubitemid 29366813)
7. Isshi K, Sakuyama T, Gen T, et al. (2007) Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phos-phoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7:335-342. (Pubitemid 36077315)
8. Kitajima M, Takita N, Hata M, et al. (2006) The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. Oncol Rep 15:161-165.
9. Koyama F, Sawada H, Fuji H, et al. (2000) Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 36:2403-2410.
10. Lancaster A, Nelson MP, Single RM, et al. (2003) PyPop: a software framework for population genomics: analyzing large-scale multi-locus genotype data. In: Altman RB, et al. (eds) Pacific Symposium on Biocomputing 8. World Scientific, Singapore, pp 514-525.
11. Marsh S, Collie-Duguid ES, Li T, et al. (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-312. (Pubitemid 29300314)
12. Ochiai T, Nishimura K, Noguchi H, et al. (2006) Prognostic impact of orotate phosphoribosyl transferase among 5-fluoro-uracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118:3084-3088.
13. Peters GJ, van Groeningen CJ, Laurensse EJ, et al. (1991) A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 68:1903-1909.
14. Pinedo HM, Peters GFJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664.
15. Suchi M, Mizuno H, Kawai Y, et al. (1997) Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet 60:525-539. (Pubitemid 27097600)
16. Tsunoda A, Nakao K, Watanabe M, et al. (2010) Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 22:355-361.
17. Ulrich CM, Curtin K, Potter JD, et al. (2005) Polymorphisms in the reduced folate carrier, thymidylate synthase, or methio-nine synthase and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 14:2509-2516. (Pubitemid 41752708)